En español

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT)

This study will investigate the safety and efficacy of a combination pharmacotherapy – extended-release depot naltrexone plus extended-release bupropion for the treatment of methamphetamine dependence.  The double-blind, placebo-controlled study includes random assignment of methamphetamine-dependent participants to one of two conditions: active medication or placebo for 8 weeks of pharmacotherapy provided with weekly psychosocial treatment.

CTN Protocol ID: 
Enrollment Status: 
Principal Investigator(s)
Walter Ling, M.D.
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.